Maxim analyst Jason McCarthy initiated Hemispherx with a Buy rating and a price target of $8, citing the company's "differentiated immune oncology approach" Ampligen which leverages the innate immune response to alter the chemokine profile in the tumor microenvironment. The analyst notes that multiple early stage combination studies are "ongoing", but as the immune oncology space grows, he sees "combinations" as the likely key that will unlock "larger market opportunities." McCarthy believes that Ampligen offers upside with data updates expected over 2019 and 2020.